How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer’s disease?

References

• Solomon B, Koppel R, Hanan E, et al. Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide. Proc Natl Acad Sci USA. 1996;93(1):452–455. doi: 10.1073/pnas.93.1.452
   PubMed Web of Science ®Google Scholar
• Kumar A, Tsao JW Alzheimer disease [internet]. Nih.Gov. StatPearls Publishing. 2019 [cited 2023 Sep 27]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499922/
   Google Scholar
• Coley N, Giulioli C, Aisen PS, et al. Randomised controlled trials for the prevention of cognitive decline or dementia: a systematic review. Ageing Research Reviews [Internet]. 2022;82:101777. [cited 2023 Sep 27]. Available from: https://www.sciencedirect.com/science/article/abs/pii/S1568163722002197
   PubMed Web of Science ®Google Scholar
• Ruan D, Sun L. Amyloid-β PET in Alzheimer’s disease: a systematic review and Bayesian meta-analysis. Brain Behav. 2022;13(1). doi: 10.1002/brb3.2850
   PubMed Web of Science ®Google Scholar
• Chen L-D, Liu W-L, Lin H-W, et al. Emerging blood exosome-based biomarkers for preclinical and clinical Alzheimer’s disease: a meta-analysis and systematic review. Neural Regen Res. 2022;17(11):2381. doi: 10.4103/1673-5374.335832
   PubMed Web of Science ®Google Scholar
• Wolgin M, Zobernig M, Dvornyk V, et al. Systematic review on saliva biomarkers in patients diagnosed with morbus Alzheimer and morbus Parkinson. Biomedicines [Internet]. 2022;10(7):1702. [cited 2023 Feb 14]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313191/
   PubMed Web of Science ®Google Scholar
• Jansen IE, van der Lee SJ, Gomez-Fonseca D, et al. Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers. Acta Neuropathol. 2022;144(5):821–842. doi: 10.1007/s00401-022-02454-z
   PubMed Web of Science ®Google Scholar
• Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–56. doi: 10.1038/nature19323
   PubMed Web of Science ®Google Scholar
• Steinbrook R. The accelerated approval of aducanumab for treatment of patients with Alzheimer disease. JAMA Intern Med. 2021;181(10):181. doi: 10.1001/jamainternmed.2021.4622
   Web of Science ®Google Scholar
• Salloway S, Chalkias S, Barkhof F, et al. Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. JAMA Neurol. 2021;79(1):79. doi: 10.1001/jamaneurol.2021.4161
   Web of Science ®Google Scholar
• Barenholtz Levy H. Accelerated approval of Aducanumab: where do we stand now? Ann Pharmacother. 2021;56(6):736–739. doi: 10.1177/10600280211050405
   PubMed Web of Science ®Google Scholar
• Largent EA, Peterson A, Karlawish J, et al. Aspiring to reasonableness in accelerated approval: anticipating and avoiding the next aducanumab. Drugs Aging. 2022;39(6):389–400. doi: 10.1007/s40266-022-00949-8
   PubMed Web of Science ®Google Scholar
• Dunn B, Stein P, Cavazzoni P. Approval of aducanumab for Alzheimer disease—the FDA’s perspective. JAMA Intern Med [Internet]. 2021;181(10):1276. Available from: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2782119
   PubMed Web of Science ®Google Scholar
• CMS. CMS finalizes medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer’s disease [internet]. Cms.Gov. CMS; 2023. [cited 2023 Aug 18]. Available from: https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-mon%20oclonal-antibodies-directed-against-amyloid-treatment
   Google Scholar
• EMA. Aduhelm: withdrawn application - European medicines agency [internet]. European Medicines Agency. European Medicines Agency. 2022. [cited 2023 Aug 18]. Available from: https://www.ema.europa.eu/en/medicines/human/withdrawn-applications/aduhelm
   Google Scholar
• National Library of Medicine. NCT05310071 [Internet]. Clinicaltrials.Gov. 2023 [cited 2023 Dec 28]. Available from: https://clinicaltrials.gov/study/NCT05310071
   Google Scholar
• FDA. Highlights of prescribing information [internet]. 2022 [cited 2023 Aug 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761178s005lbl.pdf
   Google Scholar
• Cummings J, Aisen P, Apostolova LG, et al. Aducanumab: appropriate use recommendations. J Prev Alzheimer’s Dis. 2021;8:1–13. doi: 10.14283/jpad.2021.41
   Google Scholar
• FDA. FDA grants accelerated approval for Alzheimer’s disease treatment [internet]. FDA. FDA; 2023. https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-disease-treatment
   Google Scholar
• Mahase E. Alzheimer’s disease: Lecanemab gets full FDA approval and black box safety warning. BMJ. 2023;382:1580–p1580. doi: 10.1136/bmj.p1580
   PubMedGoogle Scholar
• van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2022;388(1):9–21. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2212948
   PubMed Web of Science ®Google Scholar
• Practical Neurology. VA will cover lecanemab for Alzheimer disease [internet]. Practical Neurology. 2023. [cited 2023 Aug 18]. Available from: https://practicalneurology.com/news/va-will-cover-lecanemab-for-alzheimer-disease
   Google Scholar
• FDA. HIGHLIGHTS of PRESCRIBING INFORMATION [Internet]. 2023. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269s000lbl.pdf
   Google Scholar
• Cummings J, Apostolova L, Rabinovici GD, et al. Lecanemab: appropriate use recommendations. J Prev Alzheimer’s Dis. 2023. doi:10.14283/jpad.2023.30
   Web of Science ®Google Scholar
• Lowe SL, Willis BA, Hawdon A, et al. Donanemab (LY3002813) dose‐escalation study in Alzheimer’s disease. A&D Transl Res & Clin Interv. 2021;7(1). doi: 10.1002/trc2.12112
   PubMedGoogle Scholar
• Lowe SL, Duggan Evans C, Shcherbinin S, et al. Donanemab (LY3002813) phase 1b study in Alzheimer’s disease: rapid and sustained reduction of brain amyloid measured by florbetapir F18 imaging. J Prev Alzheimer’s Dis. 2021;1–11. doi: 10.14283/jpad.2021.56
   Web of Science ®Google Scholar
• Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512. Available from: https://jamanetwork.com/journals/jama/fullarticle/2807533?guestAccessKey=855d51a0-c676-46f8-8bb3-1ecaa471d5eb&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=071723
   PubMed Web of Science ®Google Scholar
• Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer’s Disease. N Engl J Med. 2021;384(18):1691–1704. doi: 10.1056/NEJMoa2100708
   PubMed Web of Science ®Google Scholar
• ALZForum. Donanemab | ALZFORUM [Internet]. https://www.alzforum.org. 2023. Available from: https://www.alzforum.org/therapeutics/donanemab.
   Google Scholar
• Shcherbinin S, Evans CD, Lu M, et al. Association of amyloid reduction after donanemab treatment with tau pathology and clinical outcomes. JAMA Neurol. 2022;79(10):1015. doi: 10.1001/jamaneurol.2022.2793
   PubMed Web of Science ®Google Scholar
• Pontecorvo MJ, Lu M, Burnham SC, et al. Association of donanemab treatment with exploratory plasma biomarkers in early symptomatic Alzheimer disease. JAMA Neurol [Internet]. 2022;79(12):1250. https://jamanetwork.com/journals/jamaneurology/fullarticle/2797022
   PubMed Web of Science ®Google Scholar
• Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimer’s Dis. 2022;9(2):197–210. doi: 10.14283/jpad.2022.30
   PubMed Web of Science ®Google Scholar
• Salloway S, Lee E, Papka M, et al. TRAILBLAZER-ALZ 4: topline study results directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease (S26.009). Neurology Internet. 2023;100(17_supplement_2): [[cited 2023 May 10]]. Available from: https://n.neurology.org/content/100/17_Supplement_2/3126
   Web of Science ®Google Scholar
• Rogers MB Donanemab Mops Up Plaque Faster Than Aduhelm | ALZFORUM [Internet]. http://www.alzforum.org. 2022 [cited 2023 Aug 18]. Available from: https://www.alzforum.org/news/conference-coverage/donanemab-mops-plaque-faster-aduhelm
   Google Scholar
• Liu KY, Schneider LS, Howard R. The need to show minimum clinically important differences in Alzheimer’s disease trials. Lancet Psychiatry. 2021;8(11):1013–1016. doi: 10.1016/S2215-0366(21)00197-8
   PubMed Web of Science ®Google Scholar
• Andrews JS, Desai U, Kirson NY, et al. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. Alzheimer’s & Dementia. 2019;5(1):354–363. doi: 10.1016/j.trci.2019.06.005
   Web of Science ®Google Scholar
• Van Dyck C, O’Dell RS, Mecca AP. Disease severity and minimal clinically important differences in clinical outcome assessments for Alzheimer’s disease clinical trials. A&D Transl Res Clin Interv. 2023;9(2). doi: 10.1002/trc2.12388
   Google Scholar
• Birks JS, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Of Systematic Reviews [Internet]. 2018;2(6). doi: 10.1002/14651858.CD001190.pub3
   Google Scholar
• Rubin R. Who should—and can—Get Lecanemab, the new Alzheimer disease drug? JAMA. 2023;330(15):1411. doi: 10.1001/jama.2023.14443
   PubMed Web of Science ®Google Scholar
• Ross EL, Weinberg MS, Arnold SE. Cost-effectiveness of Aducanumab and Donanemab for early Alzheimer disease in the US. JAMA Neurol. 2022;79(5):478. doi: 10.1001/jamaneurol.2022.0315
   PubMed Web of Science ®Google Scholar
• National Library of Medicine. A study to test the efficacy, safety, and tolerability of bepranemab (UCB0107) in patients with mild cognitive impairment or mild Alzheimer’s disease (AD) [Internet]. https://www.clinicaltrials.gov. 2023 [cited 2023 Dec 28]. Available from: https://www.clinicaltrials.gov/study/NCT04867616.
   Google Scholar